SynthesisFrontiers in medicine2026
Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study was to systematically evaluate the clinical efficacy and safety of dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease (KD) in children. Methods: A computerized search was conducted in databases including PubMed, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), and VIP Chinese Sci-Tech Journals Full-text Database (VIP), covering the period from the inception of each database to February 2026. We collected randomized controlled trials (RCTs) that compared the clinical efficacy and safety of dipyridamole combined with immunoglobulin and aspirin (observation group) agains immunoglobulin combined with aspirin (control group) in the treatment of KD in children, in conjunction with standard therapy. After data extraction and quality assessment of clinical studies meeting the inclusion criteria, a meta-analysis was performed using RevMan 5.3 statistical software. Results: A total of 18 RCTs involving 1,594 patients were included. The meta-analysis results indicated that the total effective rate in the observation group was significantly higher than that in the control group. Additionally, the time for clinical symptom improvement, C-reactive protein levels (CRP), erythrocyte sedimentation rate (ESR), platelet count (PLT), coronary artery lesion (CAL) and fibrinogen levels (FIB) were all significantly lower in the observation group compared to the control group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: The clinical efficacy of dipyridamole combined with immunoglobulin and aspirin in treating Kawasaki disease in children is superior to that of immunoglobulin combined with aspirin, with comparable safety. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261336468, identifier CRD420261336468.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.